Artery Implant Articles & Analysis
19 news found
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces a new study in the Journal of Cardiovascular Translational Research that examined pressure-volume profiles in heart failure patients using Daxor’s BVA-100 blood test to measure intravascular volume overload compared to a commercially available implantable pulmonary ...
MOTIV is a drug-eluting bioresorbable peripheral vascular scaffold made from REVA’s proprietary Tyrocore polymer that is designed to dissolve over time, leaving the artery free of a permanent implant and thereby allowing the artery to return to its natural movement or ...
ArterioSorb is an innovative medical implant product currently being developed by Arterius, a UK medical device micro/SME, to treat coronary artery disease (CAD). ...
The prospective, multi-center trial met all primary safety and efficacy endpoints and resulted in low rates of HF hospitalization, further validating pulmonary artery (PA) pressure-guided HF management as standard of care for NYHA class III heart failure patients. ...
The study titled, “Discordance of Pressure and Volume: Potential Implications for Pressure-Guided Remote Monitoring in Heart Failure,” sought to test the relationship (or lack thereof) between a commercially available implantable pulmonary artery pressure (PAP) monitor, estimates of cardiac blood volume, and actual circulating blood volume as ...
The BIOADAPTOR RCT is evaluating the DynamX™ Coronary Bioadaptor System, the first drug-eluting coronary artery implant that adapts to vessel physiology, allowing for the restoration of normal vessel functions essential to cardiovascular performance. ...
Food and Drug Administration (FDA) has granted approval for an amendment to the company’s PROACTIVE-HF study, a pivotal Investigational Device Exemption (IDE) trial investigating the Cordella Pulmonary Artery (PA) Pressure Sensor1, shifting the design from a randomized control study to a single-arm study. ...
The primary safety endpoint, defined as absence of periprocedural major vascular complications, major bleeding, acute kidney injury, or death within one month, was met in 96% of patients. Active Implants A new addition to the list, Memphis, TN-based Active Implants develops orthopedic implant solutions designed to complement the natural ...
This procedure consists in revascularizing the cardiac muscle, by inserting one or more implants (stents) into the arteries that supply it with blood. R-One is the first solution developed by Robocath. ...
ByRobocath
The BIOADAPTOR RCT is evaluating the DynamX™ Coronary Bioadaptor System, the first drug-eluting coronary artery implant that adapts to vessel physiology. The BIOADAPTOR RCT is a multicenter, randomized, single-blind study enrolling 444 patients from 30 centers in Europe and Japan treated with the DynamX Bioadaptor in a 1:1 randomization to Resolute ...
Braun Group of Companies and Japan-based Nipro Corporation to advance coronary artery disease management. The companies are ideally positioned to leverage shared resources to accelerate the initiation of the U.S. clinical trial of the SeQuent Please ReX to study the treatment of coronary in-stent restenosis (ISR), which is defined as the gradual re-narrowing of a coronary ...
– March 16, 2021 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced commencement of the INFINITY-SWEDEHEART randomized controlled trial (RCT) of the DynamX™ Coronary Bioadaptor System, the first metallic coronary artery implant that adapts to vessel physiology. The DynamX Bioadaptor is a metal ...
“I am excited to join Endotronix as the company prepares for commercial launch and rapid growth in this duopoly interventional heart failure segment, pulmonary artery (PA) pressure-guided HF management. And I look forward to leveraging my diverse experiences to accelerate the company along its mission to transform the standard of care for chronic heart failure ...
– January 27, 2020 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced the 24-month clinical results for the DynamX™ Coronary Bioadaptor System, the first drug-eluting coronary artery implant that adapts to vessel physiology. The results were presented at the 30th Annual Live Interventions in ...
International Trial to Compare Bioadaptor, a Novel Coronary Artery Implant Designed to Adapt to Vessel Physiology, with Traditional Drug Eluting Stents International Trial to Compare Bioadaptor, a MILPITAS, Calif. ...
-based Endotronix, Inc. and Tyndall will explore the application of novel electronics technologies to wireless, implantable sensors for chronic disease management, such as the Cordella Pulmonary Artery Pressure Sensor System (Cordella Sensor). “Together our Cordella Sensor and Cordella System provide a robust platform for data-guided chronic disease ...
The funds will be used to support the landmark PROACTIVE-HF IDE clinical trial of the Cordella Pulmonary Artery Sensor System (Cordella Sensor) and commercialization of the Cordella Heart Failure System (Cordella System). ...
The 60-patient study will evaluate safety and efficacy of the Cordella™ Pulmonary Artery Pressure Sensor System (Cordella Sensor) in support of its CE Mark submission. ...
The Cordella System is on the cusp of transforming heart failure treatment with a proactive patient management solution that improves the experience for the implanting physician, managing clinician, and patient,” Yearick said. ...